How does the licensing process differ for in-licensing and out-licensing companies?
Successful New Drug Development Strategies for Small Companies
Circulation Research Feb 3, 2012 Journal Club [Part 1] NR4A1 (Nur77) Deletion Polarizes Macrophages Toward an Inflammatory Phenotype and Increases Atherosclerosis.
Re-Engineering Early Phase Cancer Drug Development: Decreasing the Time from Novel Target to Novel Therapeutic
OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2
2013Rady
14320057 INDAH NURYANI.pdf
Cathy Tralau -Stewart PhD Head of Drug Discovery Drug Discovery Centre Imperial College
PERSONALISED MEDICINES AND THE REGULATORS Dr Mike James CambReg Consulting [email protected].
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Computational Modeling and Visualization of Biomolecules Preston J. MacDougall Middle Tennessee State University With contributions by: Dr. Christopher.
Phase 1 Study of ACE-041, a First-in-Class Inhibitor of Vascular Development in Patients with Advanced Solid and Hematologic Tumors N. G. Borgstein 1,
![Circulation Research Feb 3, 2012 Journal Club [Part 1] NR4A1 (Nur77) Deletion Polarizes Macrophages Toward an Inflammatory Phenotype and Increases Atherosclerosis.](https://static.fdocuments.net/doc/330x215/55146767550346414e8b5c04/circulation-research-feb-3-2012-journal-club-part-1-nr4a1-nur77-deletion-polarizes-macrophages-toward-an-inflammatory-phenotype-and-increases-atherosclerosis.jpg)
